CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF623 (ImmuneEditome ID:9831)

1. Gene summary of enriched editing regions for ZNF623

check button Gene summary
Gene informationGene symbol

ZNF623

Gene ID

9831

GeneSynonyms-
GeneCytomap

8q24.3

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 623
GeneModificationdate20230518
UniprotIDO75123
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr8:143638505-143639639:+ENST00000458270.2ENSG00000183309.10ZNF623intronicAluSx1,AluSp,AluSz,AluSq2chr8:143638505-143639639:+.alignment
chr8:143638505-143639639:+ENST00000526926.4ENSG00000183309.10ZNF623intronicAluSx1,AluSp,AluSz,AluSq2chr8:143638505-143639639:+.alignment
chr8:143644065-143644301:+ENST00000458270.2ENSG00000183309.10ZNF623intronicAluSzchr8:143644065-143644301:+.alignment
chr8:143644065-143644301:+ENST00000526926.4ENSG00000183309.10ZNF623intronicAluSzchr8:143644065-143644301:+.alignment
chr8:143644825-143645057:+ENST00000458270.2ENSG00000183309.10ZNF623intronicAluSz6,AluSpchr8:143644825-143645057:+.alignment
chr8:143644825-143645057:+ENST00000526926.4ENSG00000183309.10ZNF623intronicAluSz6,AluSpchr8:143644825-143645057:+.alignment
chr8:143654701-143655986:+ENST00000501748.3ENSG00000183309.10ZNF623UTR3L1ME2,AluSq2,AluJr4,AluSxchr8:143654701-143655986:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF623


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr8:143654701-143655986:+BRCAEER1.4804e-06image
ENSG00000183309.10,ZNF623BRCAEAG1.0264e-06image
chr8:143654701-143655986:+KICHEER6.1345e-04image
ENSG00000183309.10,ZNF623KICHEAG6.1345e-04image
chr8:143654701-143655986:+LIHCEER7.8185e-04image
ENSG00000183309.10,ZNF623LIHCEAG7.8185e-04image
ENSG00000183309.10,ZNF623THCAEAG4.0546e-02image
chr8:143654701-143655986:+UCECEER2.1182e-04image
ENSG00000183309.10,ZNF623UCECEAG2.1182e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000183309.10,ZNF623CESCCliEAG1.9340e-029.7800e-03-0.1531image
chr8:143654701-143655986:+CESCCliEER1.9340e-029.7800e-03-0.1531image
chr8:143654701-143655986:+KIRCPathEER9.2064e-042.4310e-020.0986image
chr8:143654701-143655986:+PAADPathEER6.9911e-039.2786e-040.2510image
ENSG00000183309.10,ZNF623PAADPathEAG6.9911e-039.2786e-040.2510image
ENSG00000183309.10,ZNF623THCAPathEAG3.5244e-021.9356e-020.1050image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF623


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:143654701-143655986:+LIHCEERENSG00000180900,SCRIB-0.44861.7426e-141.8217e-16-0.4221imageNNSCRIBMacrophages_M0GSVA_HALLMARK_MYC_TARGETS_V2
chr8:143654701-143655986:+DLBCEERENSG00000099381,SETD1A-0.67131.5499e-025.2300e-04-0.5360imageNNNAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:143654701-143655986:+DLBCEERENSG00000139410,SDSL0.67842.0596e-025.4910e-030.4418imageNNNAB_cells_naiveGSVA_HALLMARK_COAGULATION
chr8:143654701-143655986:+DLBCEERENSG00000183696,UPP10.67762.2414e-025.4825e-030.4418imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chr8:143654701-143655986:+DLBCEERENSG00000107175,CREB30.63702.4325e-021.0342e-030.5114imageNNCREB3Macrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr8:143654701-143655986:+DLBCEERENSG00000204977,TRIM13-0.65932.6879e-029.6580e-05-0.5901imageNNTRIM13B_cells_naiveGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:143654701-143655986:+DLBCEERENSG00000234616,JRK-0.64002.9236e-021.5648e-04-0.5756imageNNNAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr8:143654701-143655986:+DLBCEERENSG00000160789,LMNA0.64533.2211e-021.0821e-020.4088imageNNNAMacrophages_M0GSVA_HALLMARK_COAGULATION
chr8:143654701-143655986:+DLBCEERENSG00000185730,ZNF696-0.64303.2820e-026.0304e-04-0.5310imageNNNAB_cells_naiveGSVA_HALLMARK_COAGULATION
chr8:143654701-143655986:+DLBCEERENSG00000054116,TRAPPC30.61603.3603e-027.1724e-060.6579imageNNNAMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for ZNF623


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000183309.10,ZNF623
COADEAGMEXENSG00000141971.8chr1917406144:17406296:17413096:17413305:17422331:17422458:17423497:174236170.32691.3958e-042.2065e-130.4397imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000183309.10,ZNF623
COADEAGIRENSG00000124782.15chr67181123:7181246:7181869:71819230.20083.9498e-023.3992e-100.4334imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_ADIPOGENESIS
ENSG00000183309.10,ZNF623
KIRCEAGIRENSG00000147872.5chr919124069:19126448:19127418:191274750.20876.4881e-031.6144e-350.5830imageNAIFM1;AUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NANK_cells_activatedGSVA_HALLMARK_PEROXISOME
ENSG00000183309.10,ZNF623
KIRCEAGIRENSG00000120616.11chr1032291162:32291322:32292495:322926440.19151.1251e-029.3587e-390.6199imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RBM6;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS
ENSG00000183309.10,ZNF623
KIRCEAGIRENSG00000113721.9chr5150113841:150114038:150114749:150114958-0.20081.2077e-021.8211e-28-0.5287imageNADAR;BCCIP;BUD13;CELF2;CSTF2T;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MSI1;NOP56;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SF3A3;SF3B4;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1PDGFRBEosinophilsGSVA_HALLMARK_APICAL_JUNCTION
ENSG00000183309.10,ZNF623
KIRCEAGIRENSG00000144802.7chr3101853090:101857459:101859317:1018595230.17881.2618e-021.3647e-130.4063imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NFKBIZT_cells_follicular_helperGSVA_HALLMARK_MYOGENESIS
ENSG00000183309.10,ZNF623
KIRCEAGIRENSG00000169554.12chr2144424791:144424867:144429768:1444300260.20852.7175e-031.1643e-150.4182imageNADAR;AIFM1;AUH;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RBM6;RNF219;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARBP2;TARDBP;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184ZEB2T_cells_follicular_helperGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr8:143654701-143655986:+
MESOEERIRENSG00000104852.10chr1949102113:49102173:49104633:49104735-0.56662.8728e-028.8330e-07-0.5147imageNNNAMast_cells_restingGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:143654701-143655986:+
MESOEERIRENSG00000163703.13chr39943076:9944095:9944364:9944423-0.54673.1762e-025.8892e-06-0.4936imageNNNAT_cells_follicular_helperGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:143654701-143655986:+
MESOEERIRENSG00000113240.8chr5178616877:178616948:178617343:178617434-0.53153.3747e-021.5862e-06-0.5248imageNNNAT_cells_follicular_helperGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB

More results



Top

5. Enriched editing regions and immune infiltration for ZNF623


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr8:143654701-143655986:+ACCEERPlasma_cells1.0223e-040.4476image
ENSG00000183309.10,ZNF623ACCEAGPlasma_cells1.0223e-040.4476image
chr8:143654701-143655986:+BLCAEERMacrophages_M13.9544e-080.2740image
ENSG00000183309.10,ZNF623BLCAEAGMacrophages_M14.0451e-080.2738image
chr8:143654701-143655986:+BRCAEERMacrophages_M11.3101e-060.1467image
ENSG00000183309.10,ZNF623BRCAEAGMacrophages_M13.3515e-070.1545image
chr8:143654701-143655986:+CESCEERB_cells_memory7.8085e-060.2604image
ENSG00000183309.10,ZNF623CESCEAGB_cells_memory7.8085e-060.2604image
chr8:143654701-143655986:+COADEERMacrophages_M13.2119e-040.2240image
ENSG00000183309.10,ZNF623COADEAGMacrophages_M14.3928e-030.1778image
chr8:143654701-143655986:+DLBCEERB_cells_naive1.8188e-02-0.3813image
ENSG00000183309.10,ZNF623DLBCEAGB_cells_naive1.8188e-02-0.3813image
chr8:143654701-143655986:+ESCAEERMacrophages_M24.6271e-030.2221image
ENSG00000183309.10,ZNF623ESCAEAGMacrophages_M23.8194e-030.2268image
chr8:143654701-143655986:+HNSCEERNK_cells_resting1.1228e-020.1154image
ENSG00000183309.10,ZNF623HNSCEAGNK_cells_resting1.0608e-020.1162image
chr8:143654701-143655986:+KIRCEERMacrophages_M25.3471e-06-0.2325image
ENSG00000183309.10,ZNF623KIRCEAGDendritic_cells_activated3.1070e-030.1521image
chr8:143654701-143655986:+KIRPEERT_cells_CD4_memory_resting1.4686e-02-0.1498image
ENSG00000183309.10,ZNF623KIRPEAGT_cells_CD4_memory_resting1.4686e-02-0.1498image
chr8:143654701-143655986:+LAMLEERB_cells_memory6.6893e-030.3410image
ENSG00000183309.10,ZNF623LAMLEAGB_cells_memory1.3347e-020.3055image
chr8:143654701-143655986:+LGGEEREosinophils2.5340e-030.1321image
ENSG00000183309.10,ZNF623LGGEAGEosinophils2.5340e-030.1321image
chr8:143654701-143655986:+LIHCEERMacrophages_M02.3093e-04-0.1962image
ENSG00000183309.10,ZNF623LIHCEAGMacrophages_M02.3093e-04-0.1962image
chr8:143654701-143655986:+LUADEERPlasma_cells1.5797e-02-0.1079image
ENSG00000183309.10,ZNF623LUADEAGPlasma_cells1.6233e-02-0.1075image
chr8:143654701-143655986:+LUSCEERT_cells_CD4_memory_activated1.8375e-080.2512image
ENSG00000183309.10,ZNF623LUSCEAGT_cells_CD4_memory_activated1.8510e-080.2512image
chr8:143654701-143655986:+MESOEERMast_cells_resting1.7678e-03-0.3422image
ENSG00000183309.10,ZNF623MESOEAGMast_cells_resting1.7678e-03-0.3422image
chr8:143654701-143655986:+OVEERT_cells_CD84.8347e-090.3346image
ENSG00000183309.10,ZNF623OVEAGT_cells_CD84.2099e-090.3358image
chr8:143654701-143655986:+PAADEERT_cells_gamma_delta4.8972e-020.1499image
ENSG00000183309.10,ZNF623PAADEAGT_cells_gamma_delta4.8972e-020.1499image
chr8:143654701-143655986:+PCPGEERMacrophages_M01.2957e-040.2869image
ENSG00000183309.10,ZNF623PCPGEAGMacrophages_M01.2957e-040.2869image
chr8:143654701-143655986:+PRADEERDendritic_cells_activated2.0338e-040.1667image
ENSG00000183309.10,ZNF623PRADEAGDendritic_cells_activated2.0338e-040.1667image
chr8:143654701-143655986:+READEERPlasma_cells3.8212e-020.2201image
chr8:143654701-143655986:+SARCEERT_cells_CD4_memory_activated6.3829e-030.1721image
ENSG00000183309.10,ZNF623SARCEAGT_cells_CD4_memory_activated6.3829e-030.1721image
chr8:143654701-143655986:+SKCMEERT_cells_CD87.4659e-060.2090image
ENSG00000183309.10,ZNF623SKCMEAGT_cells_CD87.4659e-060.2090image
chr8:143654701-143655986:+STADEERMacrophages_M22.6262e-030.1634image
ENSG00000183309.10,ZNF623STADEAGMacrophages_M21.8775e-030.1683image
chr8:143654701-143655986:+TGCTEERMacrophages_M23.6954e-08-0.4245image
ENSG00000183309.10,ZNF623TGCTEAGMacrophages_M23.6954e-08-0.4245image
chr8:143654701-143655986:+THCAEERMacrophages_M21.3753e-04-0.1704image
ENSG00000183309.10,ZNF623THCAEAGPlasma_cells9.8950e-050.1737image
chr8:143654701-143655986:+THYMEERT_cells_CD4_naive7.7030e-05-0.3694image
ENSG00000183309.10,ZNF623THYMEAGT_cells_CD4_naive7.7030e-05-0.3694image
chr8:143654701-143655986:+UCECEERDendritic_cells_activated3.1464e-020.1670image
ENSG00000183309.10,ZNF623UCECEAGDendritic_cells_activated3.1464e-020.1670image
chr8:143654701-143655986:+UCSEERT_cells_CD4_memory_resting1.2171e-02-0.3359image
ENSG00000183309.10,ZNF623UCSEAGT_cells_CD4_memory_resting1.2171e-02-0.3359image
chr8:143654701-143655986:+UVMEERDendritic_cells_activated3.1573e-030.3387image
ENSG00000183309.10,ZNF623UVMEAGDendritic_cells_activated3.1573e-030.3387image


Top

6. Enriched editing regions and immune gene sets for ZNF623


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr8:143654701-143655986:+LIHCEER5.1395e-06-0.24163.6493e-06-0.24531.3903e-07-0.27773.1008e-030.1581image
ENSG00000183309.10,ZNF623LIHCEAG5.1395e-06-0.24163.6493e-06-0.24531.3903e-07-0.27773.1008e-030.1581image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000183309.10,ZNF623ACCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG7.6206e-030.3164image
chr8:143654701-143655986:+ACCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER7.6206e-030.3164image
chr8:143654701-143655986:+BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.8579e-120.3386image
ENSG00000183309.10,ZNF623BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.8295e-120.3386image
chr8:143654701-143655986:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.0984e-340.3571image
ENSG00000183309.10,ZNF623BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.6461e-300.3374image
chr8:143654701-143655986:+CESCGSVA_HALLMARK_COMPLEMENTEER1.7278e-090.3459image
ENSG00000183309.10,ZNF623CESCGSVA_HALLMARK_COMPLEMENTEAG1.7278e-090.3459image
ENSG00000183309.10,ZNF623COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.4088e-040.2362image
chr8:143654701-143655986:+COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.4131e-060.2972image
chr8:143654701-143655986:+DLBCGSVA_HALLMARK_COAGULATIONEER1.5223e-030.4965image
ENSG00000183309.10,ZNF623DLBCGSVA_HALLMARK_COAGULATIONEAG1.5223e-030.4965image
ENSG00000183309.10,ZNF623ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.6693e-040.2924image
chr8:143654701-143655986:+ESCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.8453e-040.2649image
ENSG00000183309.10,ZNF623GBMGSVA_HALLMARK_ANGIOGENESISEAG1.7710e-02-0.1867image
chr8:143654701-143655986:+GBMGSVA_HALLMARK_ANGIOGENESISEER1.7710e-02-0.1867image
chr8:143654701-143655986:+HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.5904e-070.2360image
ENSG00000183309.10,ZNF623HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.3967e-070.2368image
chr8:143654701-143655986:+KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.7036e-02-0.3045image
ENSG00000183309.10,ZNF623KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.7036e-02-0.3045image
chr8:143654701-143655986:+KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER8.3141e-05-0.2018image
ENSG00000183309.10,ZNF623KIRCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.0322e-04-0.1815image
ENSG00000183309.10,ZNF623KIRPGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.3576e-05-0.2483image
chr8:143654701-143655986:+KIRPGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.3576e-05-0.2483image
chr8:143654701-143655986:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4275e-060.2096image
ENSG00000183309.10,ZNF623LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4275e-060.2096image
chr8:143654701-143655986:+LIHCGSVA_HALLMARK_MYC_TARGETS_V2EER1.7208e-09-0.3157image
ENSG00000183309.10,ZNF623LIHCGSVA_HALLMARK_MYC_TARGETS_V2EAG1.7208e-09-0.3157image
ENSG00000183309.10,ZNF623LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.2745e-080.2510image
chr8:143654701-143655986:+LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.3579e-080.2505image
ENSG00000183309.10,ZNF623LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9131e-110.2977image
chr8:143654701-143655986:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9142e-110.2977image
chr8:143654701-143655986:+MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.3780e-040.3976image
ENSG00000183309.10,ZNF623MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.3780e-040.3976image
chr8:143654701-143655986:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2220e-150.4342image
ENSG00000183309.10,ZNF623OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.8715e-150.4338image
ENSG00000183309.10,ZNF623PAADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.4483e-040.2642image
chr8:143654701-143655986:+PAADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.4483e-040.2642image
chr8:143654701-143655986:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.0026e-030.2010image
ENSG00000183309.10,ZNF623PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.0026e-030.2010image
chr8:143654701-143655986:+PRADGSVA_HALLMARK_PEROXISOMEEER7.7407e-06-0.2001image
ENSG00000183309.10,ZNF623PRADGSVA_HALLMARK_PEROXISOMEEAG7.7407e-06-0.2001image
ENSG00000183309.10,ZNF623READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.8988e-030.2829image
chr8:143654701-143655986:+READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2335e-030.3372image
chr8:143654701-143655986:+SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.7564e-050.2679image
ENSG00000183309.10,ZNF623SARCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7564e-050.2679image
ENSG00000183309.10,ZNF623SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.1145e-090.2691image
chr8:143654701-143655986:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.1145e-090.2691image
ENSG00000183309.10,ZNF623STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.9653e-080.2991image
chr8:143654701-143655986:+STADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.4065e-090.3073image
ENSG00000183309.10,ZNF623TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.6788e-050.3304image
chr8:143654701-143655986:+TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6788e-050.3304image
chr8:143654701-143655986:+THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.5678e-120.3074image
ENSG00000183309.10,ZNF623THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.3682e-120.3040image
chr8:143654701-143655986:+THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1599e-050.4064image
ENSG00000183309.10,ZNF623THYMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.1599e-050.4064image
chr8:143654701-143655986:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3385e-030.2470image
ENSG00000183309.10,ZNF623UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3385e-030.2470image
ENSG00000183309.10,ZNF623UCSGSVA_HALLMARK_DNA_REPAIREAG3.8371e-030.3836image
chr8:143654701-143655986:+UCSGSVA_HALLMARK_DNA_REPAIREER3.8371e-030.3836image
chr8:143654701-143655986:+UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.6774e-030.3336image
ENSG00000183309.10,ZNF623UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6774e-030.3336image


Top

7. Enriched editing regions and drugs for ZNF623


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000183309.10,ZNF623ACCABT.263EAG4.5965e-020.2394image
chr8:143654701-143655986:+ACCABT.263EER4.5965e-020.2394image
chr8:143654701-143655986:+BLCACGP.60474EER9.0860e-08-0.2669image
ENSG00000183309.10,ZNF623BLCACGP.60474EAG9.3839e-08-0.2666image
chr8:143654701-143655986:+BRCACisplatinEER4.2380e-06-0.1396image
ENSG00000183309.10,ZNF623BRCACisplatinEAG1.9075e-06-0.1443image
chr8:143654701-143655986:+CESCCGP.60474EER5.4151e-06-0.2648image
ENSG00000183309.10,ZNF623CESCCGP.60474EAG5.4151e-06-0.2648image
ENSG00000183309.10,ZNF623COADAICAREAG3.1866e-04-0.2236image
chr8:143654701-143655986:+COADGefitinibEER1.1757e-03-0.2025image
chr8:143654701-143655986:+DLBCDocetaxelEER2.9174e-04-0.5558image
ENSG00000183309.10,ZNF623DLBCDocetaxelEAG2.9174e-04-0.5558image
ENSG00000183309.10,ZNF623ESCACGP.60474EAG1.0041e-05-0.3403image
chr8:143654701-143655986:+ESCACGP.60474EER4.3126e-06-0.3532image
ENSG00000183309.10,ZNF623GBMATRAEAG3.2872e-03-0.2303image
chr8:143654701-143655986:+GBMATRAEER3.2872e-03-0.2303image
chr8:143654701-143655986:+HNSCCI.1040EER4.5967e-09-0.2629image
ENSG00000183309.10,ZNF623HNSCCI.1040EAG7.8095e-09-0.2588image
chr8:143654701-143655986:+KICHGDC.0449EER1.3146e-02-0.3159image
ENSG00000183309.10,ZNF623KICHGDC.0449EAG1.3146e-02-0.3159image
chr8:143654701-143655986:+KIRCBexaroteneEER2.0811e-050.2179image
ENSG00000183309.10,ZNF623KIRCAS601245EAG8.1878e-100.3099image
ENSG00000183309.10,ZNF623KIRPGSK.650394EAG8.7759e-060.2693image
chr8:143654701-143655986:+KIRPGSK.650394EER8.7759e-060.2693image
chr8:143654701-143655986:+LGGAxitinibEER1.8530e-090.2597image
ENSG00000183309.10,ZNF623LGGAxitinibEAG1.8530e-090.2597image
chr8:143654701-143655986:+LIHCBleomycinEER1.1441e-090.3220image
ENSG00000183309.10,ZNF623LIHCBleomycinEAG1.1441e-090.3220image
ENSG00000183309.10,ZNF623LUADCI.1040EAG1.9561e-05-0.1897image
chr8:143654701-143655986:+LUADCI.1040EER1.9945e-05-0.1895image
ENSG00000183309.10,ZNF623LUSCBortezomibEAG1.3533e-04-0.1719image
chr8:143654701-143655986:+LUSCBortezomibEER1.3674e-04-0.1718image
chr8:143654701-143655986:+MESOKU.55933EER1.0572e-03-0.3573image
ENSG00000183309.10,ZNF623MESOKU.55933EAG1.0572e-03-0.3573image
chr8:143654701-143655986:+OVCHIR.99021EER1.1161e-060.2809image
ENSG00000183309.10,ZNF623OVCHIR.99021EAG1.2690e-060.2795image
ENSG00000183309.10,ZNF623PAADCCT007093EAG3.5655e-050.3088image
chr8:143654701-143655986:+PAADCCT007093EER3.5655e-050.3088image
chr8:143654701-143655986:+PCPGEHT.1864EER3.9106e-050.3073image
ENSG00000183309.10,ZNF623PCPGEHT.1864EAG3.9106e-050.3073image
chr8:143654701-143655986:+PRADGW.441756EER4.2297e-070.2257image
ENSG00000183309.10,ZNF623PRADGW.441756EAG4.2297e-070.2257image
ENSG00000183309.10,ZNF623READGDC.0449EAG5.6738e-03-0.2894image
chr8:143654701-143655986:+READBIRB.0796EER1.6314e-020.2540image
chr8:143654701-143655986:+SARCDasatinibEER1.1907e-06-0.3021image
ENSG00000183309.10,ZNF623SARCDasatinibEAG1.1907e-06-0.3021image
ENSG00000183309.10,ZNF623SKCMDasatinibEAG1.1893e-07-0.2470image
chr8:143654701-143655986:+SKCMDasatinibEER1.1893e-07-0.2470image
ENSG00000183309.10,ZNF623STADCI.1040EAG6.1966e-07-0.2668image
chr8:143654701-143655986:+STADCI.1040EER6.6439e-07-0.2669image
ENSG00000183309.10,ZNF623TGCTBMS.754807EAG1.7553e-080.4335image
chr8:143654701-143655986:+TGCTBMS.754807EER1.7553e-080.4335image
chr8:143654701-143655986:+THCACI.1040EER5.4476e-15-0.3412image
ENSG00000183309.10,ZNF623THCACI.1040EAG7.3950e-19-0.3835image
chr8:143654701-143655986:+THYMAZD6244EER2.3016e-08-0.5041image
ENSG00000183309.10,ZNF623THYMAZD6244EAG2.3016e-08-0.5041image
chr8:143654701-143655986:+UCECMidostaurinEER3.6350e-070.3826image
ENSG00000183309.10,ZNF623UCECMidostaurinEAG3.6350e-070.3826image
ENSG00000183309.10,ZNF623UCSJW.7.52.1EAG9.0391e-04-0.4350image
chr8:143654701-143655986:+UCSJW.7.52.1EER9.0391e-04-0.4350image
chr8:143654701-143655986:+UVMAZD7762EER2.6312e-03-0.3447image
ENSG00000183309.10,ZNF623UVMAZD7762EAG2.6312e-03-0.3447image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType